Startups and spinouts

2024

Enzidia ApS
Enzidia has developed a high-performance technology platform to engineer enzymes for more efficient bioprocesses. They grow their business through various forms of partnerships.

2023

BioHalo ApS
BioHalo is using cutting-edge biofluorination technology, to offer a greener and more sustainable alternative to conventional fluorochemistry practices, e.g., replacing harmful PFAS forever chemicals in various industrial formulations without compromising on performance.

2022

Ergosyn Ltd
Ergosyn is upscaling and producing biobased Ergothioneine with the aim of selling that as a supplement.

Unveil Bio ApS
Unveil Bio offers next generation DNA sequencing services to the R&D industry.

Biomia ApS
Biomia develops plant-inspired medicines to address unmet medical needs in pain, addiction, and depression.

2021

Conarium Bioworks Inc.
Conarium Bioworks is upscaling and producing biobased Melatonin with the aim of selling that both as a supplement and as a therapeutic.

NeuImmune, Inc.
NeuImmune develops innovative vaccines and biopharmaceuticals through the precision glycoengineering and delivery of biologics that address important medical and public health needs.

Scicular ApS / MATR Foods
MATR Foods transforms the plants and vegetables that the food system has rejected because of their appearance or size and give them new life through fermentation.

Nordhavn Manufactory ApS
Nordhavn Manufactory aims to become an innovative fermenting food hub entwined with the philosophy of the New Nordic movement, and with a central goal of putting true circularity into action. Nordhavn Manufactory products will be a true exercise in taste, organic produce, localism and resourcefulness.

2020

LuaBio / SecondCircle ApS / again ApS
again uses synthetic biology to convert carbon dioxide into chemical compounds that are sold back to industry. By capturing CO₂ at the point of emission and transforming it into valuable products, we help industry turn their emissions from a cost into a revenue opportunity.

Unseen Biometrics ApS
Based on a thorough analysis of the microbiome, Unseen Biometrics provide personal dietary recommendations aimed at increasing biodiversity and improving gut health for the individual.

2019

Mycropt IVS
Mycropt offers tailored solutions for biotech, biopharma, and research companies that wants to improve their protein production or diversify their product portfolio. We apply our unique platform technology to help customers enable the production of novel, difficult-to-express targets and enhance the yield of existing products.

CysBio ApS
Cysbio uses advanced metabolic engineering and synthetic biology approaches to construct bacterial cell factories for transforming the production of biochemicals from renewable feedstocks

Chrysea Ltd.
Chrysea develops precision healthy-lifespan nutritional interventions supported by rigorous clinical research, aimed at maintaining naturally occurring anti-ageing mechanisms.

Accelerbiotics ApS
Accelerbiotics develops solutions for the biotechnology and life science field. It develops electrophoresis, nucleic acid and protein purification, electroporation and electro-extraction, and other technologies.

Artisan Bio ApS/Artisan Development Labs Inc.
Artisan Bio crafts customized cell engineering solutions to solve the most challenging problems in human health applications. With facilities in Denver, Colorado and Toronto, Ontario, Artisan is building a foundry for CRISPR-driven cell therapy engineering.

Dum Data
Dum Data is developing a simple and easy to use LIMS System

Enduro Genetics ApS
Enduro is an independent service and tech provider committed to improving large-scale fermentations. By applying game-changing synthetic biology technology, they empower their partner companies to maximize performance of all cells cultivated from their production strains. By changing the desire of cells to produce, Enduro increases competitiveness of current and future green bioproduction.

2018

Octarine Bio IVS
Octarine is perfecting a biological approach to producing natural, novel, and improved cannabinoid and psychedelic molecules with tailored modes-of-action. Its proprietary technology utilizes synthetic biology, yeast fermentation and enzymatic derivatization to develop IP protected drug candidates validated in pre-clinical models.

2017

eCoute IVS
Develops an app that makes it possible to listen to abstracts from published scientific papers instead of time-consuming reading on a PC resulting in enhanced productivity.

PreDiagnose IVS
The mission of Prediagnose is to provide health care givers diagnostic tools to make confident diagnostic decisions to prolong the lives of the patients and enhance the life quality. It is the ambition to revolutionize the way microbial diseases are diagnosed by introducing simple, reliable and fast diagnostics that within a minute can identify an early infection or a virulent colonization.

Hemostasis ApS
Develops therapeutics for prevention and treatment of bleeding in elective surgery and trauma settings.

Lactobio ApS
Lactobio Aps identifies, develops, and delivers the best microbial solution for targeted problems and health related microbial dysfunctions. Lactobio has been acquired by L’Oréal in December 2023.

Utility Therapeutics Ltd
UTILITY therapeutics is dedicated to identifying, developing, and launching effective antibiotic treatment options for resistant infections.

Simo ABJ
Simo ABJ has converted into Accelerbiotics.

2016

BioPhero ApS
BioPhero’s mission is to lead the global transition towards sustainable agriculture, where safe pheromone-based products become the primary method for pest control in row crops. BioPhero has been acquired by FMC Corp. in June 2022.

ODity IVS
ODity is developing an innovative laboratory device measuring the growth of cells non-invasively enabling both speed-up and cost reduction in the bioindustrial research segment.

CloneOpt AB
CloneOpt uses proprietary technologies to ‘synthetically evolve’ a TIR so that it is highly compatible with host cell ribosomes. The process involves the generation of clone libraries that contain circa 50,000 TIRs. Protein production levels from each TIR are then experimentally evaluated and the most efficient TIR is selected.

2015

SNIPR Biome Ltd
SNIPR Biome is pioneering a novel use of CRISPR/Cas technology for microbial gene therapy. Our focus is on the development of novel, highly selective anti-bacterial drug candidates for use in difficult-to-treat conditions.

Clinical-Microbiomics A/S
Clinical Microbiomics offer expert microbiome analysis for clinical, pre-clinical and animal health studies – including DNA extraction, sequencing and profiling, and biostatistics linking the microbiome to clinical data and outcomes.

2014

Biopetrolia AB / Melt&Marble AB
Melt&Marble AB focusses on the sustainable production of fatty-acid derived products for chemicals, food ingredients, personal care products, and pharmaceuticals.

Sira Pharmaceuticals Inc.
Sira Pharmaceuticals is developing nerve growth factor fusion proteins for improving nerve growth regeneration and/or survival.

MGM BIO IVS

2012

Labster ApS
Labster is developing and delivering fully interactive advanced laboratory simulations that use gamification elements such as storytelling and scoring systems inside an immersive and engaging 3D universe. The system integrates easily with the already available learning management systems and is used worldwide.

Biosyntia ApS
Biosyntia is a start-up within synthetic biology and metabolic engineering having a unique technology and world-leading fermentation processes for production of various B-vitamins and selected nutraceuticals.

2011

UNION Therapeutics A/S
UNION is a clinical-stage, diversified pharmaceutical development company focusing on immunology and infectious diseases. Our current pipeline is comprised of two differentiated medicinal compound classes (orismilast and niclosamide) with well-characterized modes of action that have significant potential to address unmet medical needs.